BG
NVCR icon

BlackRock Group’s NovoCure NVCR Stock Holding History

BlackRock Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$121K Buy
15,498
+2,625
+20% +$21.1K ﹤0.01% 2795
2016
Q3 		$110K Buy
12,873
+1,125
+10% +$10.3K ﹤0.01% 2800
2016
Q2 		$137K Buy
+11,748
New +$147K ﹤0.01% 2690

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's NVCR Position: Q4 2016 in Review

BlackRock Group increased its NovoCure (NVCR) stake by 20% in Q4 2016, buying an estimated $21.1K and bringing the position to 15,498 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #2795.

BlackRock Group first reported a position in NVCR in Q2 2016 and has held it in 3 quarters since. The position peaked at $137K in Q2 2016. 78 funds tracked by Wall St. Rank hold NVCR as of Q4 2016.

  • BlackRock Group held 15,498 shares of NovoCure worth $121K as of Q4 2016.
  • BlackRock Group bought 2,625 NovoCure shares in Q4 2016, an estimated $21.1K.
  • NovoCure made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2795 holding.
  • BlackRock Group first reported a position in NovoCure in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Group's NovoCure position peaked at $137K in Q2 2016.
  • 78 funds tracked by Wall St. Rank held NovoCure as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.